NASDAQ · Biotechnology · USD
Aptevo Therapeutics Inc. (APVO) Stock Analysis
Aptevo Therapeutics Inc. (APVO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
APVO Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.62
- Previous Close
- $1.62
- Day's Range
- 1.60–1.65
- 52-Week Range
- 1.37–28.44
- Volume
- 7.94K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.68
Valuation
- Market Cap
- $2.90M
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$25.97M
- Shares Outstanding
- 1.81M
- 1-Year Return
- −94.34%
Dividend and dates
- Avg Volume
- 93.06K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, APVO closed at $1.60, −94.34% over 1 year.
Aptevo Therapeutics Inc. (APVO) has a market capitalization of $2.90M.
In fiscal 2025, APVO reported revenue of $0.00.
APVO Stock Return by Calendar Year
Aptevo Therapeutics Inc. (APVO) 10-year return: what $10,000 became
- 1 year
- $10,000 $566
- −94.34%
- 5 years
- $10,000 $0.002
- −99.99998%
- 10 years
- $10,000 $0.001
- −99.99999%
If you had invested $10,000 in Aptevo Therapeutics Inc. (APVO) 10 years ago, at the close on October 21, 2016, it would have been worth $0.001 at the close on October 21, 2026: −99.99999% in total, −80.37% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −83.03% |
| 2025 | −99.39% |
| 2024 | −98.54% |
| 2023 | −92.20% |
| 2022 | −70.52% |
| 2021 | −78.53% |
| 2020 | +299.67% |
| 2019 | −48.43% |
| 2018 | −70.05% |
| 2017 | +73.77% |
| 2016 (partial year) | −10.95% |
As of October 21, 2026.
APVO Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$25.97M | — |
| 2024 | $0.00 | −$24.13M | — |
| 2023 | $0.00 | −$17.41M | — |
| 2022 | $3.11M | $8.03M | 257.8% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$26.31M | −$25.97M | — |
| 2024 | $0.00 | — | −$24.60M | −$24.13M | — |
| 2023 | $0.00 | — | −$28.88M | −$17.41M | — |
| 2022 | $3.11M | — | −$28.64M | $8.03M | 257.8% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
YahooAptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
YahooAptevo Expects To Enter Investigational New Drug-Enabling Studies For Its Lead Candidate APVO451 In H1 2027
BenzingaAptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
BenzingaAptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML
InvestorsHubAptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Yahoo
All 13 articles ↓Show fewer ↑
Aptevo Reports 93% Clinical Benefit Rate With Mipletamig Triplet in Evaluable Frontline Acute Myeloid Keukemia Patients With TP53 Mutations
BenzingaAptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED COMPOSITIONS, AND METHODS".
BenzingaAptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
YahooAptevo Therapeutics Q2 EPS $(5.31) Beats $(6.16) Estimate
BenzingaAptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
YahooAptevo Therapeutics Closes Warrant Inducement Transaction, Issuing New Warrants For 1.27M Shares At $4.03 Per Share; Sells 861,708 Shares In $4.03 PIPE
BenzingaReported Earlier: Aptevo Therapeutics Announces A New Solid Strategy Designed To Fight Cancer On Multiple Fronts; Files A Patent Application Covering A Proprietary Nectin-4 X PD-L1 Dual-Targeting Backbone Designed To Strengthen Aptevo's Oncology Pipeline
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B